BioSpace News Archive

ALX Oncology Holdings Inc. announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting, which will be held in San Diego from April 5-10, 2024.

23andMe Holding Co. announced an oral presentation and two poster presentations on two of the Company’s immuno-oncology programs that will be presented at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, CA, April 5-10, 2024.

C4 Therapeutics, Inc. announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.

Merus N.V. announced the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody zenocutuzumab for poster presentation at the American Association for Cancer Research Annual Meeting 2024 taking place in San Diego, CA April 5-10, 2024.

Myeloid Therapeutics, Inc., a clinical stage immunology company, announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center.

Verastem Oncology announced that preclinical data will be presented in five posters at the American Association for Cancer Research Annual Meeting 2024 to be held on April 5-10 in San Diego, California.

AbCellera announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center.

Bonum Therapeutics announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic.

Agenus Inc. announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced four poster presentations at the American Association of Cancer Research Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA.